The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer, preferably colorectal cancer (CRC), in a subject. The method is based on the determination of the level of a panel of least one, preferably 3, 4 and most preferably at least 5, protein biomarker selected from the group consisting of the protein biomarkers Amphiregulin (AREG), Carcinoembryonic antigen (CEA), Insulin like growth factor binding protein 2 (IGFBP2), Keratin, type I cytoskeletal 19 (KRT19), Mannan binding lectin serine protease 1 (MASP1), Osteopontin (OPN), Serum paraoxonase lactonase 3 (PON3) and Transferrin receptor protein 1 (TR), in the biological sample obtained from the subject. The new biomarker panel of the invention allows diagnosing and even stratifying various cancer diseases. Furthermore, provided are diagnostic kits for performing the non-invasive methods of the invention. Since the biomarker panel of the invention provides a statistically robust method independent of the protein detection technology used, and considering that the biomarker panel of the invention is detected in plasma samples of the subjects, the invention provides an early detection screening examination that may be applied to a larger population.

There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.

Provided herein is a method for the detection and isolation of metastatic cells from a sample obtained from a subject. Also provided is a device comprising a microchip for use in the method. Also provided is a method of isolating the metastatic cells for culture and characterization. Provided herein is a kit for the method therein.

The present invention relates to a marker for diagnosing colorectal cancer, a method for providing information required for the diagnosis of colorectal cancer by using same, and a method for providing information for monitoring the response to colorectal cancer therapy by using same.

The present invention relates to the diagnosis of gastrointestinal stromal tumors (GISTs). The present invention also relates to methods and compositions for the treatment of gastrointestinal stromal tumors (GISTs).

We describe a method of diagnosing a gastric cancer. The method may include detecting the expression level of an miRNA in a sample of or from an individual. The expression level of the miRNA may be detected in an extracellular vesicle (EV) from the sample. The miRNA may be selected from the group consisting of: hsa-miR-484, hsa-miR-186-5p, hsa-miR-142-5p, hsa-miR-320d, hsa-miR-320a, hsa-miR-320b and hsa-miR-17-5p. The method may be such that an altered expression level of the miRNA as compared to the expression level of the miRNA in an EV in or of an individual known not to be suffering from gastric cancer indicates that the individual is suffering, or is likely to be suffering, from gastric cancer.

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

The invention relates to the detection of biomarkers, and methods, compositions and kits for the detection of such biological markers for diagnosing various conditions, such as cancer. In particular, the invention relates to the detection of compounds as diagnostic and prognostic markers for detecting cancer, such as oesophago-gastric cancer.

The present invention relates to a method for high-sensitivity and high-specificity detection of biomolecules by using mass spectrometry and, more specifically, to a method for high-sensitivity and high-specificity detection of proteins such as miRNA or antigens by using time-of-flight secondary ion mass spectrometry (ToF-SIMS), matrix-assisted laser desorption/ionization (MALDI), or laser desorption/ionization (LDI) mass spectrometry. The method for high-sensitivity and high-specificity detection of biomolecules by using mass spectrometry, according to the present invention, enables high-sensitivity and high-specificity detection of biomolecules by using surface mass spectrometry, and the method is expected to be used for the diagnosis and prediction of diseases by quantifying, from a biosample, a target probe such as miRNA which is known as a disease marker.

The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.